AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32152168 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest procedure
Number of subjects: 1000
Study 32152168 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 1000
Study 32152168 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor analysis
Number of subjects: 1000
Study 32152173 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intravenous 12/12 human leucocyte antigen-matched sibling cord blood cell infusion
Number of subjects: 12
Study 32152221 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells (1×10e6 CAR-T/kg)
Number of subjects: 93
Study 32152221 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Number of subjects: 93
Study 32152628 — intervention group
Group type: EXPERIMENTAL
Intervention: Plexiform neurofibromas (PNs)
Number of subjects: 122
Study 32152628 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinct nodular lesions (DNLs)
Number of subjects: 122
Study 32152628 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PNs and DNLs
Number of subjects: 122
Study 32152818 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol; Esperoct)
Number of subjects: 0
Study 32152956 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 262
Study 32153210 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32153439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense manualized treatment for 1 month as part of the ROCKETLAUNCH project
Number of subjects: 150
Study 32153439 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment in Sweden (data from the 10 previous patients at each outpatient clinic)
Number of subjects: 150
Study 32153780 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR7/8-matured dendritic cells (DCs) transfected with RNA encoding WT1, PRAME, and CMVpp65, vaccinated 10 times over 26 weeks.
Number of subjects: 10
Study 32153780 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR7/8-matured dendritic cells (DCs)
Number of subjects: 10
Study 32153804 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins concentrations in human milk
Number of subjects: 443
Study 32153804 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional and socioeconomic factors, lactation stage, and supplement intake
Number of subjects: 443
Study 32153805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-based diet for 16 weeks
Number of subjects: 100
Study 32153805 — intervention group
Group type: COMPARATOR
Intervention: National Cholesterol Education Program therapeutic lifestyle changes (TLC) diet for 16 weeks
Number of subjects: 100
Study 32153805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups participating in an aerobic exercise program
Number of subjects: 100
Study 32153817 — intervention group
Group type: EXPERIMENTAL
Intervention: DDU-supplement (500 mg DHA, 10 μg vitamin D)
Number of subjects: 16
Study 32153817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32153825 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild blueberry juice for 7 days
Number of subjects: 0
Study 32153825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32153828 — intervention group
Group type: EXPERIMENTAL
Intervention: WIC Fresh Start (WFS) lesson
Number of subjects: 0
Study 32153828 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32153829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB)
Number of subjects: 27
Study 32153829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein increase
Number of subjects: 27
Study 32153840 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Nutrition Pathway for Acute Care (INPAC) activities
Number of subjects: 700
Study 32153840 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened patients at risk for malnutrition
Number of subjects: 700
Study 32153840 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at risk for malnutrition who did not receive a dietitian assessment
Number of subjects: 700
Study 32153840 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not screened at risk who were assessed
Number of subjects: 700
Study 32153840 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to food intake noted in patient medical charts
Number of subjects: 700
Study 32153840 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients provided medication for nausea as a barrier removal strategy
Number of subjects: 700
Study 32153840 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced nutrition care strategies recorded
Number of subjects: 700
Study 32153856 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical fitness, dietary, and emotional challenges introduced in the study.
Number of subjects: 0
Study 32153856 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual dietary intake and physical activity evaluation across strata.
Number of subjects: 0
Study 32153857 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular texture menus
Number of subjects: 32
Study 32153857 — intervention group
Group type: COMPARATOR
Intervention: Pureed texture menus
Number of subjects: 32
Study 32153871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod intake twice weekly for 16 weeks (pregnancy week 20-36)
Number of subjects: 137
Study 32153871 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (control group)
Number of subjects: 137
Study 32153871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod intake
Number of subjects: 137
Study 32153879 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved supplementary food plus five anti-infective interventions
Number of subjects: 0
Study 32153879 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (3.5 kg corn/soy blended flour with 350 mL vegetable oil every two weeks)
Number of subjects: 0
Study 32153880 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week intervention to reduce sedentary behavior and cardiovascular disease risk
Number of subjects: 0
Study 32153880 — intervention group
Group type: COMPARATOR
Intervention: Sedentary Behavior (SB) group
Number of subjects: 0
Study 32153880 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle Behavior (LB) group
Number of subjects: 0
Study 32153880 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dietary quality
Number of subjects: 0
Study 32153890 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated homestead food production, food consumption, and women's empowerment interventions delivered by community health workers and agriculture extension workers through home visits and farmer field schools.
Number of subjects: 0
Study 32153890 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 0
Study 32153896 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine amoxicillin
Number of subjects: 2412
Study 32153896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready to use therapeutic food (RUTF) and standard clinical care
Number of subjects: 2412
Study 32153896 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diversity assessment
Number of subjects: 2412
Study 32153900 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily preventive zinc dispersible tablet
Number of subjects: 3400
Study 32153900 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily preventive multiple micronutrient powder
Number of subjects: 3400
Study 32153900 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic zinc dispersible tablet for diarrhea
Number of subjects: 3400
Study 32153900 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 3400
Study 32153900 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 3400
Study 32153903 — intervention group
Group type: EXPERIMENTAL
Intervention: semi-quantitative food frequency questionnaire (sqFFQ)
Number of subjects: 91
Study 32153903 — intervention group
Group type: COMPARATOR
Intervention: 2-day weighed food record
Number of subjects: 91
Study 32153909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylopass supplementation for 28 days
Number of subjects: 24
Study 32153909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32153916 — intervention group
Group type: EXPERIMENTAL
Intervention: High-PUFA diet
Number of subjects: 26
Study 32153925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FODMAP rye bread
Number of subjects: 0
Study 32153925 — intervention group
Group type: COMPARATOR
Intervention: Regular rye bread
Number of subjects: 0
Study 32153935 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Childhood Illness (IMCI) strategy implementation
Number of subjects: 514
Study 32153935 — intervention group
Group type: EXPERIMENTAL
Intervention: Health worker practices
Number of subjects: 514
Study 32153939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables vouchers over one year
Number of subjects: 91
Study 32153939 — intervention group
Group type: COMPARATOR
Intervention: Nutritional education workshops
Number of subjects: 91
Study 32153947 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g lipid-based nutrient supplement (Epi-E)
Number of subjects: 0
Study 32153951 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI-2010) dietary assessment
Number of subjects: 1745
Study 32153957 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealworms for 2 months post-surgery
Number of subjects: 168
Study 32153957 — intervention group
Group type: COMPARATOR
Intervention: Grain powder for 2 months post-surgery
Number of subjects: 168
Study 32153959 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (30,000 IU weekly for 6 months)
Number of subjects: 132
Study 32153959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 32153959 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 132
Study 32153971 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week nutrition and physical activity program including education, coping skills training, and home-based intervention
Number of subjects: 294
Study 32153971 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 294
Study 32154021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 0
Study 32154021 — intervention group
Group type: COMPARATOR
Intervention: Higher dose doxorubicin (375-600 mg/m2)
Number of subjects: 0
Study 32154325 — intervention group
Group type: EXPERIMENTAL
Intervention: IMI/REL
Number of subjects: 47
Study 32154325 — intervention group
Group type: COMPARATOR
Intervention: Colistin plus IMI
Number of subjects: 47
Study 32154359 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Number of subjects: 78
Study 32154359 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 78
Study 32154361 — intervention group
Group type: EXPERIMENTAL
Intervention: Caycedian Sophrology (8 group sessions)
Number of subjects: 0
Study 32154361 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 32154430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive AN/BQ cessation program (22-day cessation program modeled after a smoking cessation program)
Number of subjects: 0
Study 32154430 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet and cessation program
Number of subjects: 0
Study 32154430 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 0
Study 32154497 — intervention group
Group type: EXPERIMENTAL
Intervention: ULT (Iron-Enriched Supplement)
Number of subjects: 0
Study 32154499 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk-based fortifier (HMBF)
Number of subjects: 127
Study 32154499 — intervention group
Group type: COMPARATOR
Intervention: Bovine milk-based fortifier (BMBF)
Number of subjects: 127
Study 32154499 — intervention group
Group type: COMPARATOR
Intervention: HMBF and BMBF
Number of subjects: 127
Study 32154962 — intervention group
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Number of subjects: 35
Study 32155200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antiretroviral therapy (cART)
Number of subjects: 56
Study 32155200 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected controls (HUCs)
Number of subjects: 56
Study 32155200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral small-vessel diseases (CSVD) in PLHIVs
Number of subjects: 56
Study 32155200 — intervention group
Group type: COMPARATOR
Intervention: Cerebral small-vessel diseases (CSVD) in HUCs
Number of subjects: 56
Study 32156491 — intervention group
Group type: EXPERIMENTAL
Intervention: Decipher genomic classifier (GC) scores
Number of subjects: 0
Study 32156491 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 molecular subtypes
Number of subjects: 0
Study 32156491 — intervention group
Group type: EXPERIMENTAL
Intervention: Age decile
Number of subjects: 0
Study 32156630 — intervention group
Group type: EXPERIMENTAL
Intervention: IXIARO® Japanese encephalitis vaccine (2-dose primary series)
Number of subjects: 23
Study 32156743 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirabrutinib monotherapy (80 mg every day)
Number of subjects: 53
Study 32156743 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirabrutinib in combination with Idelalisib (50 mg twice a day or 100 mg every day)
Number of subjects: 53
Study 32156743 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirabrutinib in combination with Entospletinib (200 mg or 400 mg every day)
Number of subjects: 53
Study 32157282 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nonsecretors
Number of subjects: 0
Study 32157282 — intervention group
Group type: COMPARATOR
Intervention: Maternal secretors
Number of subjects: 0
Study 32157590 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl treatment
Number of subjects: 44
Study 32157590 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (somatostatin analogues)
Number of subjects: 44
Study 32158204 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual AIx measurement by applanation tonometry
Number of subjects: 76
Study 32158204 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in diffusion capacity (DLco)
Number of subjects: 76
Study 32158204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL)
Number of subjects: 76
Study 32158204 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity c-reactive protein (hsCRP)
Number of subjects: 76
Study 32158272 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin and statins offered to men with AAA after the millennium (VIVA and DANCAVAS trials)
Number of subjects: 34079
Study 32158386 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-modality exercise with mind-motor training
Number of subjects: 0
Study 32158386 — intervention group
Group type: COMPARATOR
Intervention: Active control group (M2)
Number of subjects: 0
Study 32158432 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32159070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet Intervention
Number of subjects: 0
Study 32159070 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plant protein (upper quartile, increased total protein by ≥3.3% of energy)
Number of subjects: 0
Study 32159070 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased total protein (lower quartile, decreased total protein ≥0.6% of energy)
Number of subjects: 0
Study 32160020 — intervention group
Group type: EXPERIMENTAL
Intervention: ClinGen criteria modifications applied to variants
Number of subjects: 97
Study 32160294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (5 mg twice daily plus corticosteroids)
Number of subjects: 71
Study 32160304 — intervention group
Group type: EXPERIMENTAL
Intervention: rs5780218
Number of subjects: 314
Study 32160304 — intervention group
Group type: EXPERIMENTAL
Intervention: rs708910
Number of subjects: 314
Study 32160304 — intervention group
Group type: EXPERIMENTAL
Intervention: rs932491
Number of subjects: 314
Study 32160378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep bruxism
Number of subjects: 146
Study 32160856 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration using micro-Computed Tomography (micro-CT)
Number of subjects: 87
Study 32161065 — intervention group
Group type: EXPERIMENTAL
Intervention: Modem technology for remote monitoring in domiciliary NIV
Number of subjects: 34
Study 32161368 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg weekly (part II of study 1280.1 and 1280.2)
Number of subjects: 125
Study 32161368 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab (various doses from 10-1800 mg weekly in study 1280.1 and 10-3600 mg three-weekly in study 1280.2)
Number of subjects: 125
Study 32161368 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg weekly
Number of subjects: 125
Study 32161368 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Number of subjects: 125
Study 32161547 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 62
Study 32161584 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant ipilimumab co-administration with a peptide vaccine
Number of subjects: 0
Study 32161660 — intervention group
Group type: EXPERIMENTAL
Intervention: KAPA intervention (six group sessions of motivational interviewing, monthly)
Number of subjects: 50
Study 32161660 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 32161659 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP70-exosomes detection in blood
Number of subjects: 80
Study 32161773 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-OCT in emmetropic eyes
Number of subjects: 279
Study 32161773 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-OCT in mild/moderate myopic eyes
Number of subjects: 279
Study 32161773 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-OCT in high myopic eyes
Number of subjects: 279
Study 32161773 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of tilt with axial length
Number of subjects: 279
Study 32161846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) infusions, initially every 4 weeks, then extended to every 6 weeks for the first 3 months, with subsequent intervals determined by the clinician
Number of subjects: 13
Study 32162412 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breastfed infants (EBF)
Number of subjects: 60
Study 32162412 — intervention group
Group type: COMPARATOR
Intervention: Partially breastfed infants (PBF)
Number of subjects: 60
Study 32162412 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers' breast milk iodine concentration (BMIC)
Number of subjects: 60
Study 32162412 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated iodine intake from urinary data
Number of subjects: 60
Study 32162723 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SCIT)
Number of subjects: 33
Study 32162723 — intervention group
Group type: EXPERIMENTAL
Intervention: S-desmethylcitalopram (SDCIT)
Number of subjects: 33
Study 32162723 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SCIT) and S-desmethylcitalopram (SDCIT)
Number of subjects: 33
Study 32162826 — intervention group
Group type: EXPERIMENTAL
Intervention: Married or partnered patients
Number of subjects: 367
Study 32162826 — intervention group
Group type: COMPARATOR
Intervention: Single patients
Number of subjects: 367
Study 32163181 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial Embolisation (TAE)
Number of subjects: 61
Study 32163181 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolisation (TACE)
Number of subjects: 61
Study 32163181 — intervention group
Group type: COMPARATOR
Intervention: No active therapeutic intervention (Control)
Number of subjects: 61
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Chikungunya infection (acute phase)
Number of subjects: 193
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 193
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 193
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 193
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertigo
Number of subjects: 193
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Vomiting
Number of subjects: 193
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 193
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rehydration
Number of subjects: 193
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea levels
Number of subjects: 193
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Enthesitis
Number of subjects: 193
Study 32163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenosynovitis
Number of subjects: 193
Study 32163431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Text Messaging Intervention
Number of subjects: 0
Study 32163431 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32163613 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 15
Study 32163613 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not treated with denosumab)
Number of subjects: 15
Study 32163631 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPP-children
Number of subjects: 150
Study 32163639 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong desire to void (SDV)
Number of subjects: 30
Study 32163639 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-void (PV)
Number of subjects: 30
Study 32163675 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful revascularization (TIMI Flow 3 post-PCI)
Number of subjects: 158
Study 32163675 — intervention group
Group type: EXPERIMENTAL
Intervention: One-vessel disease
Number of subjects: 158
Study 32163675 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel disease
Number of subjects: 158
Study 32163675 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrhythmic complications during PCI
Number of subjects: 158